Vinva Investment Management Ltd Raises Stock Position in Boston Scientific Corporation $BSX

Key Points

• Vinva Investment Management raised its stake 83.2% to 124,760 shares of Boston Scientific (worth ~$12.1M), joining several large institutions (Norges Bank, Parnassus, Egerton, Jennison, Edgewood) in materially increasing positions as ~89.1% of the stock is institutionally owned.
• Major Wall Street firms have trimmed price targets (e.g., JPMorgan to $100, RBC to $115), yet the consensus remains a "Moderate Buy" with an average target of $108.36 and most analysts rating the stock Buy/Outperform.
• Corporate catalysts and risks include a newly approved $5 billion share buyback and an investor event at the ACC on March 28, offset by a legal overhang from multiple class-action lawsuit filings that could pressure the stock.

Vinva Investment Management Ltd lifted its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 83.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 124,760 shares of the medical equipment provider's stock after acquiring an additional 56,645 shares during the quarter. Vinva Investment Management Ltd's holdings in Boston Scientific were worth $12,107,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Norges Bank purchased a new position in Boston Scientific in the second quarter valued at about $2,089,937,000. Edgewood Management LLC purchased a new stake in shares of Boston Scientific in the second quarter worth about $746,655,000. Parnassus Investments LLC grew its stake in shares of Boston Scientific by 42,978.9% in the third quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider's stock valued at $672,128,000 after buying an additional 6,868,459 shares in the last quarter. Egerton Capital UK LLP grew its stake in shares of Boston Scientific by 223.7% in the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider's stock valued at $518,660,000 after buying an additional 3,671,548 shares in the last quarter. Finally, Jennison Associates LLC raised its holdings in shares of Boston Scientific by 133.5% during the 3rd quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider's stock valued at $482,170,000 after buying an additional 2,823,744 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on BSX shares. Royal Bank Of Canada reduced their price target on Boston Scientific from $130.00 to $115.00 and set an "outperform" rating on the stock in a research report on Thursday, February 5th. Stifel Nicolaus dropped their price objective on shares of Boston Scientific from $125.00 to $110.00 and set a "buy" rating on the stock in a research note on Wednesday, February 4th. JPMorgan Chase & Co. reduced their target price on shares of Boston Scientific from $135.00 to $100.00 and set an "overweight" rating on the stock in a research report on Thursday, February 5th. Robert W. Baird decreased their target price on shares of Boston Scientific from $118.00 to $101.00 and set an "outperform" rating for the company in a research note on Thursday, February 5th. Finally, Oppenheimer dropped their price target on shares of Boston Scientific from $125.00 to $100.00 and set an "outperform" rating on the stock in a research note on Friday, January 16th. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $108.36.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Board increased share buyback authorization to $5 billion, which supports EPS and provides a buyback backstop that can limit downside and return capital to shareholders. Boston Scientific (BSX) Raises Share Buyback Authorization To $5B
• Positive Sentiment: Boston Scientific will host an investor event and live webcast at the American College of Cardiology meeting on March 28 to discuss clinical data — a chance for management to highlight growth drivers and reassure investors on clinical/market progress. Boston Scientific to host investor event at the 75th Annual Scientific Session of the American College of Cardiology
• Neutral Sentiment: Coverage and commentaries note BSX is about 6% lower since last earnings — analysts point to mixed cues from the earnings release (modest beat on EPS, revenue roughly in line, and guidance ranges) and market reactions to forward views; this helps explain recent selling pressure but is not new company-specific bad news. Why Is Boston Scientific (BSX) Down 6% Since Last Earnings Report?
• Negative Sentiment: A wave of securities-class-action filings and investor-alert notices from multiple law firms allege wrongdoing for purchasers between July 23, 2025 and Feb 3, 2026 — several firms (Robbins LLP, Rosen, Bernstein Liebhard, Faruqi & Faruqi, Levi & Korsinsky, Gainey McKenna & Egleston) have issued notices and reminder deadlines, creating a legal overhang that can pressure the stock and increase uncertainty/costs. BSX Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Rosen Law Firm Urges Boston Scientific Stockholders to Contact the Firm Bernstein Liebhard Investor Alert

Boston Scientific Price Performance

BSX stock opened at $71.24 on Friday. The stock's 50 day moving average is $85.03 and its two-hundred day moving average is $94.55. Boston Scientific Corporation has a 52-week low of $70.75 and a 52-week high of $109.50. The company has a market capitalization of $105.71 billion, a PE ratio of 36.72, a P/E/G ratio of 1.00 and a beta of 0.69. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company had revenue of $5.29 billion during the quarter, compared to analysts' expectations of $5.29 billion. During the same period in the prior year, the business posted $0.70 EPS. The business's revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. This represents a 10.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.